Albertsons Companies Inc - Class A
Q3 2025 Earnings
Did ACI Beat Earnings? Q3 2025 Results
Albertsons delivered a profit beat in its fiscal third quarter but fell just short on the top line, painting a mixed picture for the grocery chain as it navigates pharmacy-driven growth against margin headwinds. Adjusted EPS of $0.72 cleared the $0.68 consensus by 5.60%, while revenue of $19.12 billion grew 1.9% year over year but came in fractionally below the $19.17 billion estimate. The primary story behind both figures was pharmacy: surging prescription volumes powered a 2.4% identical sales gain and a 21% jump in digital sales, yet the lower-margin pharmacy mix, combined with higher delivery and handling costs, compressed gross margin to 27.4% from 27.9% a year ago. Loyalty membership expanded 12% to 49.8 million members, underscoring the company's longer-term engagement strategy. Looking ahead, Albertsons narrowed its fiscal 2025 adjusted EPS outlook to $2.08 to $2.16, while flagging a 65 to 70 basis point headwind in the fourth quarter tied to Medicare drug price negotiations, a pressure point that has already drawn cautious analyst scrutiny around the broader 2026 outlook.
- Identical sales increased 2.4%, driven primarily by strong pharmacy sales growth
- Digital sales increased 21%
- Loyalty members increased 12% to 49.8 million
- Selling and administrative expenses as a percentage of revenue improved due to sales leveraging of employee costs and lower merger-related costs
- Productivity initiatives partially offset increasing wage rates and inflationary pressures
“In the third quarter, we delivered solid results and continued to advance our strategic priorities. Our investments in technology and AI are fundamentally reshaping how we operate and serve our customers; driving smarter decisions, greater efficiency, and more personalized experiences. Growth in our digital and pharmacy channels, combined with disciplined execution and targeted investments, is strengthening our value proposition and positioning us for success.”
Albertsons CEO, on the earnings call
Forward Guidance & Outlook
Updated fiscal 2025 outlook: Identical sales growth of 2.2% to 2.5% (narrowed from 2.2% to 2.75%); Adjusted EBITDA of $3.825 billion to $3.875 billion, including approximately $65 million from a 53rd week (narrowed from $3.8 billion to $3.9 billion); Adjusted net income per share of $2.08 to $2.16 (narrowed from $2.06 to $2.19); Effective income tax rate of 23% to 24% (improved from 23.5% to 24.5%); Capital expenditures of $1.8 billion to $1.9 billion (unchanged). The company flagged a 65–70 basis point negative impact in Q4 from the Inflation Reduction Act's Medicare Drug Price Negotiation Program effective January 1, 2026, resulting in lower pharmacy sales.
ACI YoY Financials
Figures from SEC filings and company reports. Not investment advice.